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Abstract
We present a case of acute myeloid leukemia (AML) with myelodysplasia-related changes that
presented as thrombotic thrombocytopenic purpura (TTP). Our patient presented with the
classic pentad of TTP symptoms: anemia, thrombocytopenia, fever, elevated creatinine, and
altered mental status. After a failure to respond to plasmapheresis therapy, we proceeded with
a bone marrow biopsy and fluorescent in situ hybridization, which supported formal diagnosis
of AML with myelodysplasia-related changes. Our case is an extremely rare presentation of a
rare condition, as there have been no reported cases of AML with myelodysplasia-related
changes presenting as TTP.
Categories: Pathology, Oncology, Hematology
Keywords: thrombotic thrombocytopenic purpura, acute myeloid leukemia, microangiopathic
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Introduction
Acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes abnormal
myeloblasts, red blood cells, or platelets. Proliferation of abnormal cells in the bone marrow
interferes with normal production of normal blood cells [1]. Classically, patients present with
lethargy, easy bleeding and bruising, and increased risk of infection. Thrombotic
thrombocytopenic purpura (TTP) is a rare blood disorder caused by antibodies against the
enzyme ADAMTS13, which results in the fragmentation of platelets by uncleaved von
Willebrand multimers and subsequent formation of blood clots in microvasculature throughout
the body. Classically, these patients present with low-grade fevers, anemia, thrombocytopenia,
acute kidney injury, altered mental status, and schistocytes on peripheral blood smear [2]. We
present a patient whose clinical presentation aligned with TTP, but upon further investigation,
was found to have a rare form of AML.
Case Presentation
This is a 75-year-old male who presented to the emergency department with altered mental
status, non-bloody diarrhea, subjective fevers, and intermittent epistaxis, each of which had
been present for the past two weeks. Past medical history was notable for non-insulin-
dependent diabetes mellitus, paroxysmal atrial fibrillation, anticoagulated with apixaban 5 mg
twice daily, and hypertension. The patient's vital signs were notable for a temperature of
98.6°F, a heart rate of 98 bpm, a blood pressure of 110/78 mmHg, a respiratory rate of 18, and
an oxygen saturation of 96%. At this time, physical exam was notable for a lethargic, obese male
in no acute distress, epistaxis from right nostril, 3/6 crescendo-decrescendo murmur in the
right upper sternal border, hepatosplenomegaly, and petechiae scattered across the patient’s
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bilateral lower extremities.
Parameter (units) Value
Hemoglobin (g/dL) 9.2
Mean corpuscular volume (fL) 76
White blood cells (/µL) 8,500
Platelets (/µL) 11,000
Creatinine (mg/dL) 1.5
Prothrombin time (seconds) 17.1
Partial thromboplastin time (seconds) 36.5
D-Dimer (µg/mL) 1.67
Fibrinogen (mg/dL) 630
Lactic acid dehydrogenase (units/L) 605
Haptoglobin (mg/dL) 243
Reticulocyte count (cells/µL) 0.008
TABLE 1: Patient's Laboratory Values on Presentation
The patient's creatinine was increased from a baseline of 1.1, which was recorded one month
prior to presentation. The complete blood count was re-ordered following a transfusion of one
unit of platelets, which was notable for a decrease in platelets from 11,000 per µL to 9,000 per
µL.
Non-contrast computerized tomography (CT) of the patient’s abdomen featured
hepatosplenomegaly (Figure 1). At this time, a peripheral blood smear was ordered, which was
remarkable for 2% schistocytes without blasts. The patient underwent plasmapheresis
treatment for suspected TTP for a total of five days. The patient did not respond to therapy, as
his platelets continued to oscillate between 8,000 and 12,000 µL.
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FIGURE 1: Hepatosplenomegaly with few non-specific hepatic
nodules.
After the plasmapheresis was completed, the decision was made to proceed with a bone marrow
biopsy and fluorescent in situ hybridization, which was remarkable for a long arm deletion on
chromosome 5, which supported a formal diagnosis of AML with myelodysplasia-related
changes.
Throughout the entire hospital course, the patient was given 11 units of packed red blood cells
and 12 units of platelets for sustained anemia and thrombocytopenia, respectively. Following
consultation with hematology, due to the patient’s age and comorbidities, the decision was
made to treat him with a five-day course of decitabine, a low-intensity chemotherapy drug.
Following consultation with nephrology, the patient was placed on dialysis for the duration of
chemotherapy for tumor lysis syndrome prophylaxis. On day 13 of his hospitalization, the
patient and family elected for supportive care. On the morning of day 14, the patient was
pronounced dead due to complications from AML and subsequent treatment.
Discussion
Although AML with myelodysplastic changes is a common subset of acute leukemias, this case
is particularly rare because of the patient's presentation. Since the patient presented with the
classic pentad of TTP symptoms (fever, anemia, thrombocytopenia, acute kidney injury, and
altered mental status) and 2% schistocytes were seen on peripheral blood smear, diagnosis of
AML was consequently delayed.
Even though anemia, thrombocytopenia, and fever are characteristic symptoms of leukemia, it
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is rare for AML to present with acute kidney injury, acute change in mental status, and
decreasing platelets following platelet transfusion [1]. This is the first reported case of AML
with myelodysplastic changes that presented with the classic pentad of TTP symptoms,
schistocytes on peripheral smear, and absence of myeloblasts on peripheral smear.
Relying on the classic presentation of TTP symptoms is unreliable, as only 20%-30% of patients
present with the pentad [3]. Moreover, the presence of schistocytes is not specific for TTP. In
fact, in TTP, schistocytes typically range between 3% and 10% [4]. Schistocytes may also be seen
in disseminated intravascular coagulation (DIC), hemolytic uremic syndrome (HUS), and
malfunctioning heart valves [4].
In our patient, increased haptoglobin, increased fibrinogen, and absence of bloody diarrhea
made TTP, DIC, and HUS less likely, respectively. Moreover, the severely low reticulocyte count
made malignancy or aplastic anemia much more likely. However, since the patient's platelets
remained <15,000/µL throughout his hospitalization, a bone marrow biopsy to confirm a
diagnosis of acute leukemia was delayed. Without a formal diagnosis, we elected for
plasmapheresis exchange transfusion since it is recommended in any patient with suspected
TTP due to mortality as high as 90% without treatment [2].
Although AML is a relative rare disease, it is the most common acute leukemia in adults [5].
Non-Hispanic white males have a higher incidence than other racial and ethnic groups and the
median age at diagnosis is 65 years of age [5].
The etiologies of underlying chromosomal abnormalities in most cases of AML are largely
unknown [6]. The WHO 2008 classification of AML categorizes the condition into subtypes,
which aids in diagnosis and prognosis [7]. Our patient was found to have a 5q deletion, which
most often occurs in elderly patients with prior myelodysplastic syndrome and is associated
with rapid deterioration and poor prognosis [8]. Our patient’s prognosis was especially poor
considering he had possible metastatic lesions in his liver and spleen [8].
Treatment of AML is largely based on the patient’s age, comorbidities, current functional
status, and goals of treatment at time of diagnosis, as treatment is highly variable and may
actually decrease life expectancy [9]. In patients with AML with deletions of chromosome 5q,
there is insufficient data to predict the possibility of complete remission in elderly patients
with comorbidities [10]. However, delaying treatment has been associated with a decreased rate
of complete remission and decreased life expectancy by three to five months in select patient
populations [11,12].
Conclusions
There have been no reported cases of AML with myelodysplasia-related changes presenting as
TTP. Early diagnosis of AML in elderly patients is especially important due to the rapid
progression of this disease. In summation, this case shows that AML should be under
consideration in elderly patients presenting with unexplained cytopenias and constitutional
symptoms, even in the absence of blasts on peripheral blood smear. It is important to diagnose
AML in its early stages and manage it appropriately in order to prolong survival and increase
the chances of complete remission. This case highlights the importance of a high clinical index
of suspicion for AML in patients who present with unexplained cytopenias and constitutional
symptoms even when there are distracting symptoms and an absence of blasts on peripheral
smear.
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